Rapamycin ameliorates chitosan nanoparticle-induced developmental defects of preimplantation embryos in mice

Yun-Jung Choi1, Sangiliyandi Gurunathan1, DaSom Kim1

  • 1Department of Stem Cell and Regenerative Biotechnology, Humanized Pig Research Center (SRC), Konkuk University, Seoul, Republic of Korea.

Oncotarget
|July 28, 2016
PubMed

Insights

Chitosan nanoparticles (CSNPs) harm mouse embryonic development by inducing stress and cell death. Rapamycin treatment mitigated these harmful effects, offering potential for safer nanomaterial applications.

Area of Science:

  • Nanotechnology
  • Developmental Biology
  • Toxicology

Background:

  • Chitosan nanoparticles (CSNPs) are utilized as drug and gene delivery systems.
  • The impact of CSNPs on embryonic development requires further investigation.

Purpose of the Study:

  • To elucidate the effects of CSNPs on mouse preimplantation embryonic development.
  • To evaluate the protective role of rapamycin against CSNP-induced developmental toxicity.

Main Methods:

  • Investigated CSNP internalization in mouse blastocysts.
  • Assessed CSNP-induced endoplasmic reticulum (ER) stress, reactive oxygen species (ROS), and autophagy.
  • Evaluated the effects of CSNPs and rapamycin on embryonic development and epigenetic reprogramming in vivo and in vitro.

Main Results:

  • CSNPs were internalized into mouse blastocysts, inducing ER stress, ROS production, and cell death.
  • Rapamycin treatment reduced CSNP-induced mitochondrial dysfunction, apoptosis, oxidative stress, ER stress, and autophagy.
  • CSNPs exhibited toxicity to ovarian follicles, while rapamycin rescued oxidative stress-related embryonic defects and modulated key gene expression.

Conclusions:

  • Rapamycin can ameliorate CSNP-induced developmental defects in preimplantation embryos.
  • Understanding CSNP toxicity is crucial for developing safer nanomaterials for therapeutic use.

Related Concept Videos